文献速递消化、代谢与肾脏急症心脑血管急症

协调照护优化2型糖尿病心血管预防治疗:一项随机临床试验

Coordinated Care to Optimize Cardiovascular Preventive Therapies in Type 2 Diabetes: A Randomized Clinical Trial.
PubMed 文献 · JAMA · 2023-01-01
一句话结论在2型糖尿病合并动脉粥样硬化性心血管疾病的成人中,协调多层面干预较常规照护提高三类循证治疗同时处方率(37.9% vs 14.5%,校正OR 4.38)。

这项美国43家心脏科门诊的整群随机临床试验纳入1049例2型糖尿病合并动脉粥样硬化性心血管疾病、且未同时使用全部三类循证治疗(高强度他汀、ACEI或ARB、SGLT2抑制剂和/或GLP-1受体激动剂)的成人。干预包括评估局部障碍、制定照护路径、协调照护、教育临床医生、向门诊反馈数据及为参与者提供工具。主要终点为入组后6至12个月时三类治疗同时处方的比例,干预组37.9%(173/457) vs 常规照护组14.5%(85/588),差异23.4%(校正OR 4.38,95%CI 2.49-7.71;P<.001)。干预未伴随动脉粥样硬化性心血管疾病危险因素的变化,复合次要终点(全因死亡或心肌梗死、卒中、失代偿性心力衰竭或紧急血运重建住院)干预组5%(23/457) vs 常规照护组6.8%(40/588)(校正HR 0.79,95%CI 0.46-1.33),但试验未把握度检验该差异。

要点

  • 协调多层面干预使2型糖尿病合并动脉粥样硬化性心血管疾病成人三类循证治疗同时处方率从14.5%升至37.9%(校正OR 4.38,95%CI 2.49-7.71;P<.001)。
  • SGLT2抑制剂和/或GLP-1受体激动剂处方变化最大:干预组12.3%升至60.4%,常规照护组14.5%升至35.5%(校正OR 3.11,95%CI 2.08-4.64)。
  • 高强度他汀处方干预组66.5%升至70.7%,常规照护组58.2%降至56.8%(校正OR 1.73,95%CI 1.06-2.83)。
  • ACEI或ARB处方干预组75.1%升至81.4%,常规照护组69.6%降至68.4%(校正OR 1.82,95%CI 1.14-2.91)。
  • 复合次要终点干预组5%(23/457) vs 常规照护组6.8%(40/588)(校正HR 0.79,95%CI 0.46-1.33),试验未把握度检验该差异。

适用人群与场景

  • 美国43家心脏科门诊招募的2型糖尿病合并动脉粥样硬化性心血管疾病成人,且未同时使用全部三类循证治疗(高强度他汀、ACEI或ARB、SGLT2抑制剂和/或GLP-1受体激动剂)。

处置流程与药物剂量

  • 干预措施包括:评估局部障碍、制定照护路径、协调照护、教育临床医生、向门诊反馈数据及为参与者提供工具。
  • 干预目标为在入组后6至12个月时处方全部三类循证治疗:高强度他汀、ACEI或ARB、SGLT2抑制剂和/或GLP-1受体激动剂。

研究设计与关键结果

  • 整群随机临床试验,43家美国心脏科门诊,纳入1049例参与者(干预组459例来自20家门诊,常规照护组590例来自23家门诊);中位年龄70岁,女性338例(32.2%),黑人173例(16.5%),西班牙裔90例(8.6%)。
  • 末次随访(97.3%参与者为12个月)时,干预组三类治疗同时处方173/457(37.9%) vs 常规照护组85/588(14.5%),差异23.4%(校正OR 4.38,95%CI 2.49-7.71;P<.001)。
  • 高强度他汀处方从基线到随访:干预组66.5%升至70.7%,常规照护组58.2%降至56.8%(校正OR 1.73,95%CI 1.06-2.83)。
  • ACEI或ARB处方从基线到随访:干预组75.1%升至81.4%,常规照护组69.6%降至68.4%(校正OR 1.82,95%CI 1.14-2.91)。
  • SGLT2抑制剂和/或GLP-1受体激动剂处方从基线到随访:干预组12.3%升至60.4%,常规照护组14.5%升至35.5%(校正OR 3.11,95%CI 2.08-4.64)。
  • 干预未伴随动脉粥样硬化性心血管疾病危险因素的变化。
  • 复合次要终点(全因死亡或心肌梗死、卒中、失代偿性心力衰竭或紧急血运重建住院)干预组23/457(5%) vs 常规照护组40/588(6.8%)(校正HR 0.79,95%CI 0.46-1.33);试验未把握度检验该差异。

证据类型、等级与局限

  • 证据类型:整群随机临床试验。
  • 试验注册号:ClinicalTrials.gov NCT03936660。
  • 局限:试验未把握度检验复合次要终点的差异。

对床旁实践的改变

  • 在2型糖尿病合并动脉粥样硬化性心血管疾病且未同时使用三类循证治疗的成人中,协调多层面干预(评估障碍、制定照护路径、协调照护、教育临床医生、反馈数据、提供工具)可增加三类治疗同时处方的比例。
  • 干预未伴随动脉粥样硬化性心血管疾病危险因素的变化;复合次要终点差异未达统计学显著(校正HR 0.79,95%CI 0.46-1.33),试验未把握度检验该差异。

指南或共识出处

  • JAMA发表的Coordinated Care to Optimize Cardiovascular Preventive Therapies in Type 2 Diabetes: A Randomized Clinical Trial(NCT03936660)。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: Evidence-based therapies to reduce atherosclerotic cardiovascular disease risk in adults with type 2 diabetes are underused in clinical practice.

OBJECTIVE: To assess the effect of a coordinated, multifaceted intervention of assessment, education, and feedback vs usual care on the proportion of adults with type 2 diabetes and atherosclerotic cardiovascular disease prescribed all 3 groups of recommended, evidence-based therapies (high-intensity statins, angiotensin-converting enzyme inhibitors [ACEIs] or angiotensin receptor blockers [ARBs], and sodium-glucose cotransporter 2 [SGLT2] inhibitors and/or glucagon-like peptide 1 receptor agonists [GLP-1RAs]).

DESIGN, SETTING, AND PARTICIPANTS: Cluster randomized clinical trial with 43 US cardiology clinics recruiting participants from July 2019 through May 2022 and follow-up through December 2022. The participants were adults with type 2 diabetes and atherosclerotic cardiovascular disease not already taking all 3 groups of evidence-based therapies.

INTERVENTIONS: Assessing local barriers, developing care pathways, coordinating care, educating clinicians, reporting data back to the clinics, and providing tools for participants (n = 459) vs usual care per practice guidelines (n = 590).

MAIN OUTCOMES AND MEASURES: The primary outcome was the proportion of participants prescribed all 3 groups of recommended therapies at 6 to 12 months after enrollment. The secondary outcomes included changes in atherosclerotic cardiovascular disease risk factors and a composite outcome of all-cause death or hospitalization for myocardial infarction, stroke, decompensated heart failure, or urgent revascularization (the trial was not powered to show these differences).

RESULTS: Of 1049 participants enrolled (459 at 20 intervention clinics and 590 at 23 usual care clinics), the median age was 70 years and there were 338 women (32.2%), 173 Black participants (16.5%), and 90 Hispanic participants (8.6%). At the last follow-up visit (12 months for 97.3% of participants), those in the intervention group were more likely to be prescribed all 3 therapies (173/457 [37.9%]) vs the usual care group (85/588 [14.5%]), which is a difference of 23.4% (adjusted odds ratio [OR], 4.38 [95% CI, 2.49 to 7.71]; P < .001) and were more likely to be prescribed each of the 3 therapies (change from baseline in high-intensity statins from 66.5% to 70.7% for intervention vs from 58.2% to 56.8% for usual care [adjusted OR, 1.73; 95% CI, 1.06-2.83]; ACEIs or ARBs: from 75.1% to 81.4% for intervention vs from 69.6% to 68.4% for usual care [adjusted OR, 1.82; 95% CI, 1.14-2.91]; SGLT2 inhibitors and/or GLP-1RAs: from 12.3% to 60.4% for intervention vs from 14.5% to 35.5% for usual care [adjusted OR, 3.11; 95% CI, 2.08-4.64]). The intervention was not associated with changes in atherosclerotic cardiovascular disease risk factors. The composite secondary outcome occurred in 23 of 457 participants (5%) in the intervention group vs 40 of 588 participants (6.8%) in the usual care group (adjusted hazard ratio, 0.79 [95% CI, 0.46 to 1.33]).

CONCLUSIONS AND RELEVANCE: A coordinated, multifaceted intervention increased prescription of 3 groups of evidence-based therapies in adults with type 2 diabetes and atherosclerotic cardiovascular disease.

TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03936660.

来源:JAMA,查看原文。版权归原作者所有。

参考来源

  1. Pagidipati NJ, Nelson AJ, Kaltenbach LA, et al. Coordinated Care to Optimize Cardiovascular Preventive Therapies in Type 2 Diabetes: A Randomized Clinical Trial. JAMA. 2023. PMID: 36877177. doi:10.1001/jama.2023.2854

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。